A multiple-sclerosis drug that was at the center of Sanofi's $20 billion takeover battle for Genzyme three years ago was approved for sale in Europe on Tuesday, the drug's first regulatory approval world-wide.
Reported by Wall Street Journal 3 hours ago.
↧